The Incidence and Risk of Venous Thromboembolism Associated With Cancer and Nonsurgical Cancer Treatment

被引:45
作者
Falanga, Anna [1 ]
机构
[1] Osped Riuniti Bergamo, Dept Hematol Oncol, Ctr Thrombosis & Hemostasis, I-24128 Bergamo, Italy
关键词
Cancer; Chemotherapy; Hormonal therapy; Venous thromboembolism; Prophylaxis; Guidelines; DEEP-VEIN THROMBOSIS; FATAL PULMONARY-EMBOLISM; LOW-DOSE WARFARIN; MULTIPLE-MYELOMA; DOUBLE-BLIND; RECEIVING THALIDOMIDE; HOSPITALIZED-PATIENTS; RANDOMIZED-TRIAL; CLINICAL-TRIAL; BREAST-CANCER;
D O I
10.1080/07357900802563028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with cancer are at high risk of developing venous thromboembolism, a risk that varies according to the type of malignancy and its disease stage, and is steadily increased by concomitant patient-related thrombotic risk factors, such as advanced age, infection, heart disease, respiratory disease, as well as hospitalization, surgical, and nonsurgical cancer treatments. Current evidence-based guidelines raise awareness of the importance of thromboprophylaxis in hospitalized cancer patients and highlight the thrombotic risks of combined chemotherapy regimens. Therefore, they recommend that all patients hospitalized or bedridden owing to cancer should be considered for thromboprophylaxis in the absence of contraindications to anticoagulant therapy.
引用
收藏
页码:105 / 115
页数:11
相关论文
共 83 条
[21]  
Falanga A, 2003, HAEMATOLOGICA, V88, P607
[22]  
Falanga Anna, 2007, Hematology Am Soc Hematol Educ Program, P165
[23]   Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer [J].
Fisher, B ;
Dignam, J ;
Wolmark, N ;
DeCillis, A ;
Emir, B ;
Wickerham, DL ;
Bryant, J ;
Dimitrov, NV ;
Abramson, N ;
Atkins, JN ;
Shibata, H ;
Deschenes, L ;
Margolese, RG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (22) :1673-1682
[24]   A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS [J].
FISHER, B ;
COSTANTINO, J ;
REDMOND, C ;
POISSON, R ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
WOLMARK, N ;
WICKERHAM, DL ;
FISHER, ER ;
MARGOLESE, R ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J ;
PATERSON, AHG ;
FELDMAN, MI ;
FARRAR, W ;
EVANS, J ;
LICKLEY, HL ;
KETNER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :479-484
[25]   Mechanisms of disease: Mechanisms of thrombus formation [J].
Furie, Bruce ;
Furie, Barbara C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (09) :938-949
[26]   Prevention of venous thromboembolism [J].
Geerts, William H. ;
Bergqvist, David ;
Pineo, Graham F. ;
Heit, John A. ;
Samama, Charles M. ;
Lassen, Michael R. ;
Colwell, Clifford W. .
CHEST, 2008, 133 (06) :381S-453S
[27]   PHASE-I AND PHARMACOKINETIC STUDY OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GIVEN IN COMBINATION WITH FLUOROURACIL PLUS CALCIUM LEUCOVORIN IN METASTATIC GASTROINTESTINAL ADENOCARCINOMA [J].
GREM, JL ;
MCATEE, N ;
MURPHY, RF ;
HAMILTON, JM ;
BALIS, F ;
STEINBERG, S ;
ARBUCK, SG ;
SETSER, A ;
JORDAN, E ;
CHEN, A ;
KOHLER, DR ;
KOTITE, B ;
ALLEGRA, CJ .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) :560-568
[28]   Risk factors for deep vein thrombosis and pulmonary embolism -: A population-based case-control study [J].
Heit, JA ;
Silverstein, MD ;
Mohr, DN ;
Petterson, TM ;
O'Fallon, WM ;
Melton, LJ .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (06) :809-815
[29]   Relative impact of risk factors for deep vein thrombosis and pulmonary embolism - A population-based study [J].
Heit, JA ;
O'Fallon, WM ;
Petterson, TM ;
Lohse, CM ;
Silverstein, MD ;
Mohr, DN ;
Melton, LJ .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (11) :1245-1248
[30]   Non-small cell lung cancer and antiangiogenic therapy: What can be expected of bevacizumab? [J].
Herbst, RS ;
Sandler, AB .
ONCOLOGIST, 2004, 9 :19-26